What is a Generic Drug?
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Mavyret (Glecaprevir/Pibrentasvir)
Also Known as maviret
Prescription Required
We don't have this generic product yet!
Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.
-
Product Details
Description
Mavyret (glecaprevir and pibrentasvir) is a prescription medication used to treat adults and pediatric patients who are at least 3 years of age with a certain chronic hepatitis C virus (HCV) genotype infection with or without compensated cirrhosis or with HCV genotype 1 infection who was previously treated with either an HCV NS5A inhibitor OR an NS3/4A protease inhibitor.
Mavyret is available in an oral tablet containing 100 mg glecaprevir and 40 mg pibrentasvir. It is also available in oral pellets containing 50 mg glecaprevir and 20 mg pibrentasvir.
Fact Table
Formula
C38H46N6O9•C57H65F5N10O8
License
US FDA, EMA
Bioavailability
Glecaprevir: 51% (oral), Pibrentasvir: 76% (oral)
Legal status
Prescription only
Chemical Name
Glecaprevir: (3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(2S)-1-[(2S)-2-(methoxycarbonyl)pyrrolidin-1-yl]-4-methylpentan-2-yl]carbamoyl}propyl]-10-(2-{2-[methoxy(methyl)amino]pyridin-4-yl}oxyethoxy)-4,5,6,7,8,10,11,12,13,14,15,16,24,24a-tetradecahydro-2H,21H-7,12-methanocyclopropa[19,20]cyclopropa[7,8]cyclohepta[1,2-b]naphthalen-10-yl carbamate, Pibrentasvir: Methyl (2S)-1-[(2S)-2-[5-[3,5-difluoro-4-[4-[4-[4-(2-fluorophenyl)piperidin-4-yl]phenyl]benzimidazol-1-yl]phenyl]-1H-indol-1-yl]-1,1,3,3-tetramethylbutylcarbamoyl]pyrrolidine-2-carboxylate
Elimination half-life
Glecaprevir: 6 hours, Pibrentasvir: 23 to 29 hours
Dosage (Strength)
100 mg Glecaprevir/40 mg Pibrentasvir per tablet (300 mg/120 mg per dose)
Pregnancy
Consult a doctor
Brands
Mavyret
Protein binding
Glecaprevir: 97.5%, Pibrentasvir: 99.9%
PubChem CID
Glecaprevir: 44603563, Pibrentasvir: 46215243
MedlinePlus
a617043
ChEBI
Glecaprevir: CHEBI:134722, Pibrentasvir: CHEBI:134723
ATC code
J05AP57
DrugBank
Glecaprevir: DB13879, Pibrentasvir: DB13878
KEGG
Glecaprevir: D10750, Pibrentasvir: D10749
Routes of administration
Oral
Directions
Mavyret should be taken as directed by the prescribing doctor, who will determine an appropriate treatment regimen based on the age and weight of the patient.
Patients may refer to the medication guide that comes with their prescription for further instructions for use.
Store at or below 30°C (86°F) and out of children’s reach.
Talk to your doctor or pharmacist about any questions or concerns you have.
Ingredients
The active ingredients in Mavyret include glecaprevir and pibrentasvir.
Inactive ingredients in the tablets include colloidal silicon dioxide, copovidone (type K 28), croscarmellose sodium, hypromellose 2910, iron oxide red, lactose monohydrate, polyethylene glycol 3350, propylene glycol monocaprylate (type II), sodium stearyl fumarate, titanium dioxide, and vitamin E (tocopherol) polyethylene glycol succinate.
Inactive ingredients in the oral pellets include colloidal silicon dioxide, copovidone (type K 28), croscarmellose sodium, hypromellose 2910, iron oxide red, iron oxide yellow, lactose monohydrate, polyethylene glycol/macrogol 3350, propylene glycol monocaprylate (type II), sodium stearyl fumarate, titanium dioxide, and vitamin E (tocopherol) polyethylene glycol succinate.
Contraindications
Patients with moderate or severe liver impairment or who have had liver decompensation should not take Mavyret.
Patients should not take Mavyret with atazanavir or rifampin.
Cautions
- Mavyret contains the following FDA Boxed Warning:
- Reactivation of hepatitis B virus has been reported and has resulted in, in some cases, fulminant liver inflammation, liver failure, and death.
- Before you or your child starts treatment with Mavyret, tell the doctor about:
- All the prescription and over-the-counter medications you or your child takes
- You or your child’s allergies
- You or your child’s current health problems and past medical history
- You or your child’s pregnancy or breastfeeding status
- Mavyret medication contains the following warnings and precautions:
- Risk of hepatitis B virus reactivation
- Risk of liver decompensation or failure in patients with evidential advanced liver disease
Side Effects
Headache and fatigue are the most common Mavyret side effects; however, other side effects may also occur.
Immediately inform your doctor of any side effects that bother you or your child or won’t go away.
With a valid prescription, you can buy Mavyret right here!
Reference
Mavyret. North Chicago, IL: AbbVie Inc.; 2023.
IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.Product Code : 14600
-
Product Reviews
